Is there any Indian generic version of Alpelisib?

Alpelisib (Alpelisib) is a targeted therapy drug that belongs to the PI3K inhibitor category. Its main function is to interfere with the proliferation and survival mechanism of tumor cells by inhibiting PI3Kα enzyme. PI3K (Phosphatidylinositol-3-kinase) is an enzyme that plays a key role in cell biology and is involved in regulating cell growth, differentiation and survival. Abnormally activated PI3K pathway is closely related to the occurrence and development of various cancers, including breast cancer.

Apelis has not yet been launched in China, so it is not included in medical insurance. Therefore, patients cannot purchase it domestically and need to purchase Apelis through overseas channels.

There is only an Indian version of the original Apelis drug, and there is no Indian generic version. Abroad, the main Apelvis original drug is the European version and the Indian version. The European version of the original drug costs tens of thousands of yuan. Relatively speaking, the Indian version of the original drug costs around four to five thousand yuan. The price is relatively cheap. Moreover, the European version of the original drug and the Indian version of the original drug are consistent in composition and efficacy.

Apelix is special in that it selectively inhibits the α isoform of PI3K without affecting other PI3K isoforms. This subtype selectivity allows the drug to more precisely intervene in the abnormally activated PI3K signaling pathway, resulting in better efficacy and lower toxic and side effects.

This drug is mainly used to treat advanced or metastatic breast cancer that carries PIK3CA gene mutations that are hormone receptor-positive (HR+) and human epidermal growth factor receptor 2-negative (HER2-). PIK3CAGene mutation is one of the most common molecular mutations in breast cancer, and the development and application of Apelvis allows doctors to more accurately develop treatment plans for patients with this genetic mutation.